SCHEMBL2407686

SCHEMBL2407686

Oc1ccc(Cl)cc1-c1ccc(-c2nnn[nH]2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.50
IDO1 P14902 5/20 0.48
KMT2A Q03164 8/20 0.46
MEN1 O00255 7/20 0.46
MAPT P10636 6/20 0.46
HPGD P15428 6/20 0.46
LMNA P02545 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
ALOX15 P16050 2/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
MCL1 Q07820 1/20 0.39
EPHX2 P34913 1/20 0.39
ALOX12 P18054 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
USP2 O75604 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2406795 0.87 MEN1 (0.46) PIM1IDO1KMT2AMEN1MAPT
SCHEMBL17254301 0.80 SNCA (0.35) KMT2AMEN1MAPTALOX15ALOX12
SCHEMBL1774400 0.80 ALPL (0.46) HPGDMAPK1SMN1; SMN2NPC1RAB9A
SCHEMBL2406770 0.78 ALDH1A1 (0.45) KMT2AMEN1MAPTHPGDLMNA
SCHEMBL2404778 0.78 HPGDS (0.35) PIM1IDO1KMT2AMEN1MAPT
SCHEMBL8217792 0.78 ESR2 (0.46) HSD17B10PIK3CA
SCHEMBL6849506 0.78 ALDH1A1 (0.48) IDO1KMT2AMEN1HPGDALOX15
SCHEMBL4339179 0.75 ALOX5 (0.47) IDO1KMT2AMEN1MAPTHPGD
SCHEMBL2028396 0.74 ADH5 (0.32)
SCHEMBL17751101 0.74 NPC1 (0.38) KMT2AMEN1HPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US claimed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP claimed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP claimed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO claimed
US-20150093356-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2015-04-02 US disclosed
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
US-20110212054-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC. 2011-09-01 US disclosed
US-7790704-B2 Thrombopoietin mimetics GlaxoSmithKline, LLC (US) 2010-09-07 US disclosed
US-7674887-B2 Thrombopoietin mimetics GLAXOSMITHKLINE LLC (US) 2010-03-09 US disclosed
US-7648971-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP. (US) 2010-01-19 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
US-20090176973-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2009-07-09 US disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070179192-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION AND GLAXO GROUP LIMITED 2007-08-02 US disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-7160870-B2 Thrombopoietin mimetics SMITHKLINE BEECHAM CORPORATION (US) 2007-01-09 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PIM1 3132/4885IDO1 471/4885KMT2A 1838/4885
US-20070179192-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PIM1 3132/4885IDO1 471/4885KMT2A 1838/4885
US-20150093356-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PIM1 3132/4885IDO1 471/4885KMT2A 1838/4885
US-20110212054-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PIM1 3132/4885IDO1 471/4885KMT2A 1838/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PIM1 3132/4885IDO1 471/4885KMT2A 1838/4885
US-20090176973-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK PIM1 3132/4885IDO1 471/4885KMT2A 1838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.